Wave Life Sciences Ltd. (1U5)
XFRA 
Summary
1U5 Chart
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data
Wave Life Sciences Ltd. retains a Strong Buy rating, driven by near-term Accelerated Approval catalysts for WVE-N531 and WVE-006. The company is on track to file an NDA for WVE-N531 in DMD exon 53 skipping in 2026, targeting approval based on dystrophin production and functional testing. Recent phase 1b/2a data for WVE-006 in AATD showed up to 70.5% Z-AAT reduction with multi-dosing, with key FDA feedback and 600 mg multi-dose data expected in mid/late 2026.
Wave Life Sciences Ltd. (1U5) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Wave Life Sciences Ltd. ever had a stock split?
Wave Life Sciences Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Paul Bolno CEO | XFRA Exchange | SG9999014716 ISIN |
| SG Country | 317 Employees | - Last Dividend | - Last Split | 11 Nov 2015 IPO Date |
Overview
Wave Life Sciences Ltd. is at the forefront of biotechnology, focusing on the design, development, and commercialization of revolutionary ribonucleic acid (RNA) medicines. Leveraging their proprietary PRISM discovery and drug development platform, the company is dedicated to transforming the treatment landscape for both rare and common disorders. This platform integrates versatile modalities, innovative chemistry, and advanced insights into human genetics to craft scientific breakthroughs. Established in 2012 and headquartered in Singapore, Wave Life Sciences is a clinical-stage company that embarks on strategic collaborations with industry giants like GlaxoSmithKline, Takeda Pharmaceutical Company Limited, and Asuragen, Inc., to enhance the reach and efficacy of its RNA therapeutics.
Products and Services
- WVE-006
- siRNA clinical candidate for Obesity and Metabolic Disorders
- WVE-N531
- WVE-003
An RNA editing oligonucleotide under development for treating alpha-1 antitrypsin deficiency. This innovative approach aims to directly modify the RNA responsible for the disorder, offering a potential new approach to treatment.
A specialized small interfering RNA (siRNA) therapeutic aimed at addressing obesity and other metabolic disorders. This candidate demonstrates the company's commitment to tackling prevalent, complex health issues through targeted RNA interference mechanisms.
An exon skipping oligonucleotide designed to treat Duchenne muscular dystrophy. This product reveals the potential of RNA-based therapies to correct genetic mutations and restore normal function, particularly in diseases caused by specific genetic errors.
An antisense silencing oligonucleotide targeting Huntington's disease (HD). By inhibiting the production of the harmful proteins that cause HD, WVE-003 represents a cutting-edge approach to treating this devastating neurodegenerative disorder.
